Figure 8.

HSV-1 dICP0–treated tumor-bearing mice have higher antigen-specific cytotoxic CD8⁺ T cells. (a) Percentage of HER-2–specific CD8⁺ T cells in the peripheral blood of treated tumor-bearing BALB/c mice. Blood samples were processed, and cells were restimulated with the HER-2–immunodominant epitope peptide and stained for the cell surface marker CD8 and intracellular IFN-γ to identify HER-2–specific CD8⁺ T cells (n = 5 for each treatment). The χ² test was used to test the statistical significance of the differences in proportion of antigen-specific CD8⁺ T cells. (b) Viability assessed by measurement of cellular metabolism in TUBO cells left untreated or cocultured with CD8⁺ T splenocytes harvested from tumor-bearing mice treated with PBS or HSV dICP0. The values are average of three wells that used pooled splenocytes from five mice. ***P < 0.0005.